Product Images Venlafaxine Hydrochloride

Venlafaxine is a Extended-Release Tablets that comes in a blue point package of 30 tablets. The usual dosage is once daily and it needs to be stored at a temperature between 15°C and 30°C. Each tablet contains 150 mg of Venlafaxine hydrochloride USP. The medication guide must be given to the patient with each dispensed tablet. It was manufactured by Ascent Pharmaceuticals and distributed by Blue Point Laboratories.*

This is a description of a medication called Venlafaxine extended-release tablets, which is available in a package of 30 tablets. The medication is for prescription only and each tablet contains 225mg of Venlafaxine hydrochloride. The medication should be given to the patient along with a medication guide. The medication should be stored in a cool and dry place, with excursions allowed within a certain temperature range. It is manufactured by Ascent Pharmaceuticals, Inc. for Blue Point Laboratories.*

This is a prescription medication called Venlafaxine that comes in extended-release tablets. The recommended dose is once a day, and each tablet contains 37.5 mg of Venlafaxine hydrochloride. The medication should be stored between 15°C - 30°C and protected from moisture and humidity. The manufacturer is Ascent Pharmaceuticals, and it is being distributed by Blue Point Laboratories. The package insert contains dosage information, and the dispenser is instructed to give the attached medication guide to the patient each time the medication is dispensed.*

This is a description of Venlafaxine Extended-Release Tablets by Blue Point Laboratories. The medication is only available by prescription and each tablet contains 75mg of venlafaxine hydrochloride. The recommended dosage is once daily and the package insert should be consulted for dosage instructions. The tablets should be stored at 25°C and protected from moisture and humidity. Ascent Pharmaceuticals, Inc. manufacture the medication for Blue Point Laboratories.*

This text appears to be a list of warning signs for suicidal thoughts, including increased depression, anxiety, agitation, and unusual behavior. It also mentions physical symptoms such as sleeplessness and visual problems. The text emphasizes the importance of seeking help if one experiences these symptoms.*

This table shows the incidence of insomnia and nervousness in placebo-controlled major depressive disorder and other trials. The trials involved Venlafaxine Hydrochloride and Placebo Extended-Release Capsules, and the sample sizes ranged from 2357 to 695. The percentage occurrence of insomnia and nervousness in the trials is also provided.*

The given text appears to be a table showing the incidence of treatment-emergent adverse reactions in short-term placebo-controlled clinical trials with Venlafaxine Hydrochloride extended-release capsules in patients with major depressive disorder. The table shows the percentage of individuals reporting reactions for different body systems such as body as a whole, cardiovascular system, metabolic/nutritional, nervous system, respiratory system, skin, special senses, urogenital system, etc. The reactions and their corresponding percentage rates are mentioned along with the number of patients who have experienced them while taking Venlafaxine Hydrochloride extended-release capsules and placebo.*

This is a table showing the difference in the number of cases of suicidality per 1000 patients treated with certain drugs compared to a placebo. The table shows that some drugs can result in an increase or decrease in cases of suicidality when compared to the placebo. There are specific numbers given for each drug, showing the difference in cases of suicidality.*

This table shows the number and percentage of sustained elevations in systolic diastolic blood pressure in premarketing studies of Venlafaxine Hydrochloride Extended-Release Capsule for Major Depressive Disorder (doses ranging from 75-375 mg/day) and other clinical trials (doses ranging from 75-225 mg/day). The data indicates that out of 197705 patients, 3% experienced sustained elevations in SDBP for Major Depressive Disorder while only 0.6% experienced the same for other clinical trials.*

This is a table showing the mean changes in supine systolic and diastolic blood pressure for patients with Major Depressive Disorder and other clinical trials following treatment with Venlafaxine Hydrochloride Extended-Release Capsules compared to a placebo. The table indicates the study duration, indication, and 2ad dose in placebo-controlled trials. The results are presented according to supine systolic and diastolic blood pressure. No additional information is available.*